Item 8.01 Other Events.

On December 17, 2025, Sutro Biopharma, Inc. (the "Company") received notice from the Listing Qualifications staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1). As of December 16, 2025, the closing bid price of the Company's common stock had been at least $1.00 per share for 10 consecutive business days, and the Company satisfies all other applicable criteria for continued listing on The Nasdaq Global Market. As a result of this determination, the listing matter is now closed.

As previously disclosed, on June 20, 2025, the Company received notice from the Staff of Nasdaq that, because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1).